Lev Radin/Pacific Press/picture alliance A 300-year-old Stradivarius violin was sold at an auction in New York on Friday for $11.3 million (€10.9 million), according to Sotheby's auction house.

Whether it’s snagging an elite rookie card, landing a prized autograph, or pulling a super rare parallel, the 2025 Topps Series 1 Baseball set is delivering across every category. But this year ...

MANILA, Philippines — Tech innovator Converge ICT Solutions Inc. has secured a rare certification for its ... Converge yesterday said it has secured a Tier 3 certification for the development ...

New York: A rare Stradivarius violin, made over 300 years ago by Antonio Stradivari during his so-called golden period, fetched $11.3 million at auction in New York on Friday, Sotheby's said.

New Miami Heat forward Andrew Wiggins is about to join a rare club featuring two of the ... Wiggins averages 17.6 points, 4.6 rebounds, and 2.3 assists. However, his 44.4 shooting percentage ...

The president’s son is accused of shooting a protected rare duck in the Venice Lagoon. It comes after video surfaced showing him surrounded by dead birds he and his group allegedly shot in a protected ...

Dominick's, which has been serving up breakfast and diner fare for nearly 70 years ... up on restaurant concept in Erie From food truck to 3 restaurant locations in 4 years: Cheeserie expanding ...

--(BUSINESS WIRE)--Cure Rare Disease (CRD) announced it has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of an antisense ...

After hours: February 7 at 4:05:05 PM EST Loading Chart for RARE ...

Maira Ansari is the anchor of WAVE News at 3 and co-anchor of WAVE News at 5, 5;30 and 6. She joined WAVE News in February 2007. She is a proud mother of two children -- a boy and girl. Prior to ...

Speaking about how season 2 is going to be more "complex" and lean into more horror aspects of the series, showrunners ... who’s so rare, who’s so self-confident, literate, smart, weird ...

French biotech Pharnext has seen the value of its shares collapse after it revealed that its lead drug, a treatment for Charcot-Marie-Tooth (CMT) disease, failed to make the grade in a phase 3 trial.